News
-
Phase 3 MISSION Trial Of Nexavar (Sorafenib) In Patients With Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint Of Improving Overall Survival
5/22/2012
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar® (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.
-
FDA Issues Alert On Potential Dangers Of Unproven Treatment For Multiple Sclerosis
5/10/2012
The U.S. Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called “liberation therapy” or the “liberation procedure” to treat chronic cerebrospinal venous insufficiency (CCSVI).
-
Rexahn Pharmaceuticals Submits Archexin Phase II Protocol For Ovarian Cancer To FDA
5/8/2012
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, recently announced that it has submitted a Phase II protocol for the clinical study of Archexin as a treatment of ovarian cancer to the U.S. Food and Drug Administration (FDA).
-
Prana Enrolls First Patient In The ‘Reach2HD’ Phase II Huntington Disease Trial
4/30/2012
Prana Biotechnology (NASDAQ: PRAN) (ASX: PBT) today announced that the first patient has been dosed in the "Reach2HD Trial" - a 6 month Phase IIa clinical trial testing PBT2, the Company's drug in development for Huntington disease
-
Merck Presents Results Of A Phase I Clinical Trial Evaluating Investigational BACE Inhibitor MK-8931 At American Academy Of Neurology
4/27/2012
Merck, known as MSD outside the United States and Canada, recently presented Phase I data evaluating the safety and tolerability of its novel, oral β-amyloid precursor protein site cleaving enzyme (BACE) inhibitor, MK-8931, being investigated as a potential treatment for Alzheimer's disease.
-
Galenea To Receive $6M From The Stanley Medical Research Institute To Progress Pro-Cognitive Drug Discovery And Development Program
4/26/2012
Galenea Corp., a leader in the rapidly emerging field of synaptic transmission, today announced that The Stanley Medical Research Institute (SMRI) will provide $6 million in an equity investment to support the development of Galenea's innovative pro-cognitive discovery program and the selection of a clinical candidate for the treatment of schizophrenia and other psychiatric disorders.
-
Novartis Drug Afinitor® Approved By FDA As First Medication To Treat Patients With Non-Cancerous Kidney Tumors Associated With TSC
4/26/2012
Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets* for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery(2).
-
Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinson's Disease
4/20/2012
A recent clinical trial conducted at Evergreen Healthcare shows that a new form of a common drug used to treat Parkinson's Disease greatly improves the quality of life for patients and reduces the affects of symptoms such as tremors, slowness, stiffness and difficulty walking.
-
Worldwide Clinical Trials Receives Recognition From ISR The CRO To Have On Your Radar
4/17/2012
Worldwide Clinical Trials Inc., a leading global provider of clinical research services, recently acknowledged receipt of strong ratings and recommendations from one of the industry’s leading independent market research firms, Industry Standard Research (ISR).
-
FDA Approves Amyvid™ (Florbetapir F 18 Injection) For Use In Patients Being Evaluated For Alzheimer's Disease And Other Causes Of Cognitive Decline
4/10/2012
Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.